Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Athenex, Inc.
Recent submissions include what could be the fourth novel agent approved under the RTOR pilot.
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Hanmi is accelerating development of a plant-derived COVID-19 vaccine with Bioapp after successful early, the forming part of the leading South Korean pharma group’s post-pandemic business vision, which includes 'green biotech'.
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
- Other Names / Subsidiaries
- QuaDPharma, LLC., Kinex Pharmaceuticals, Axis Therapeutics Limited